Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][15]. Core Insights - The company is expected to benefit from accelerated domestic market share growth due to the recent restrictions on Illumina, a global leader in gene sequencing, which has been placed on an unreliable entity list by the Chinese Ministry of Commerce [6][10]. - The company reported a revenue increase of 10.28% year-on-year for 2024, driven by enhanced sales of gene sequencers and related laboratory equipment, with a significant 89.6% growth in Q4 revenue [4][5]. - The company is positioned as a leader in the domestic sequencing industry, with projections for revenue growth from 32.1 billion yuan in 2024 to 47.55 billion yuan in 2026, alongside a potential return to profitability by 2026 [7][11]. Company Overview - The latest closing price of the company's stock is 81.06 yuan, with a total market capitalization of 338 billion yuan and a circulating market value of 173 billion yuan [3]. - The company has a total share capital of 4.17 billion shares, with 2.13 billion shares in circulation [3]. - The company’s largest shareholder is Shenzhen Huada Technology Holdings Group [3]. Financial Performance - For 2024, the company expects to achieve a total revenue of 32.1 billion yuan, with a net loss of 5.99 billion yuan, which is a reduction in losses compared to the previous year [4][11]. - The company’s total assets as of the end of 2024 are projected to be 103.3 billion yuan, reflecting a 2.10% decrease year-on-year [4]. - The company’s operating expenses increased by approximately 13% due to adjustments in marketing strategies aimed at expanding application promotion and channel development [5]. Profitability Forecast - The company is projected to have a net profit of -5.99 billion yuan in 2024, improving to -0.03 billion yuan in 2025, and returning to a profit of 2.06 billion yuan in 2026 [7][11]. - The expected earnings per share (EPS) are forecasted to improve from -1.46 yuan in 2023 to 0.50 yuan in 2026 [11][14].

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company has shown strong performance in Q4 2024, with a significant increase in revenue and a positive outlook for domestic market opportunities due to the accelerated domestic substitution in the gene sequencing industry [2][3] - The company is expected to benefit from the inclusion of Illumina in the entity list, which provides an opportunity to capture market share [2] - The company has made substantial progress in its overseas localization strategy, enhancing its global production and service capabilities [3] Financial Performance - In 2024, the company achieved revenue of 3.21 billion yuan, a year-on-year increase of 10.28%, and a net profit attributable to shareholders of -599 million yuan, a year-on-year increase of 1.38% [1] - For Q4 2024, the company reported revenue of 1.34 billion yuan, a year-on-year increase of 89.61% and a quarter-on-quarter increase of 103.28% [1] - The company has a strong order backlog of 820 million yuan as of Q3 2024, with 520 million yuan from the domestic market and 300 million yuan from overseas [4] Revenue and Profit Forecast - Revenue forecasts for 2024-2026 are 3.21 billion yuan, 3.70 billion yuan, and 4.23 billion yuan, representing year-on-year growth rates of 10.3%, 15.2%, and 14.4% respectively [4] - Net profit forecasts for the same period are -599 million yuan, -196 million yuan, and -73 million yuan, with year-on-year growth rates of 1.4%, 67.2%, and 63.0% respectively [4] Market Position and Strategy - The company has established 23 domestic subsidiaries and 24 overseas subsidiaries, along with 9 R&D centers and 7 production bases globally [3] - The company has enhanced its marketing and channel expansion efforts, leading to a significant increase in the installation of gene sequencers [2][3]

Core Viewpoint - The article highlights the debut of BGI Genomics' new generation of AI+robotics for laboratory automation, marking a significant advancement towards fully automated laboratory processes [1] Group 1: Product Features - The new aLab Robot features both collaborative and compound robotic systems designed specifically for laboratory environments [1] - The robots are capable of operating in confined spaces with high precision and efficiency, making them ideal for laboratory automation tasks [1] - The system is intended to meet various needs such as material transportation, flexible loading and unloading, and integration of functional islands [1]

华大智造 摘要 • 华大智造重组业务，整合单机自动化、智慧实验室及微流控部门，提供从 样本存储到计算存储的整体解决方案，旨在通过新技术赋能，迎合全球实 验室建设趋势。 • 华大智造将生成式 AI 应用于实验室自动化，与北京脑科学所、上海交通大 学深海所等合作，提供全流程解决方案，并计划扩展至合成生物学、智慧 农业等领域。 • 华大智造推出智能一体机器人平台 Offer Two，对标 OpenAI，并致力于 优化用户体验，使科研工作者和临床用户能够灵活定制模块并运行各种应 用程序。 • 华大智造开发基于图像传感器自发光原理的半导体测序仪，已获国家药监 局三类医疗器械注册证，并于 2024 年第四季度开始累计新增装机超过 300 台，该设备利用手机 CMOS 摄像头进行信号传感和读取，无需激光器。 • 华大智造结合蛋白质大语言模型和强化学习，开发 EvolvePlay 算法，用 于蛋白质定向进化，优化荧光素酶，提高检测效率，相关研究已在 《Nature Artificial Intelligence》上发表。 Q&A 华大智造在生命科学自动化领域的最新进展是什么？ 从 2025 年开始，华大智造对生命科学自动化业 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-013 深圳华大智造科技股份有限公司 关于变更会计政策的公告 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 （三）变更后采用的会计政策 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别提示： 本次会计政策变更系根据中华人民共和国财政部（以下简称"财政部"）发 布的《企业会计准则解释第 17 号》及《企业会计准则解释第 18 号》的相关规定 进行的相应变更，无需提交公司董事会和股东大会审议，不会对公司财务状况、 经营成果和现金流量产生重大影响。 一、 本次会计政策变更概述 （一）会计政策变更的主要内容 2023 年 10 月，财政部发布《企业会计准则解释第 17 号》（财会〔2023〕21 号），规定了"关于流动负债与非流动负债的划分""关于供应商融资安排的披露" "关于售后租回交易的会计处理"的相关内容，该解释规定自 2024 年 1 月 1 日 起 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-012 深圳华大智造科技股份有限公司 2024年度业绩快报 | 归属于母公司所有者的每股 | 19.38 | 20.81 | -6.87 | | --- | --- | --- | --- | | 净资产（元） | | | | 注：1.本报告期初数同法定披露的上年年末数。 2.计算基本每股收益、加权平均净资产收益率、归属于母公司所有者的每股净 资产时，考虑了库存股的影响。 本公告所载2024年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以深圳华大智造科技股份有限公司（以下简称"公司"）2024年年度的 定期报告为准，提请投资者注意投资风险。 一、2024年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | | --- | --- | --- | --- | --- | | 营业总收入 | 321,038.73 | 291,122.23 | | 10.28 | | 营业利润 | -53,161.41 | -60,679.15 | | 不适用 | | 利润总额 | -53,659. ...

证券代码：688114 证券简称：华大智造 公告编号：2025-011 深圳华大智造科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 2 月 26 日 （二） 股东大会召开的地点：深圳市盐田区梅沙街道云华路 9 号华大时空 中心 C 区国际会议中心 419 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股 东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 120 | | --- | --- | | 普通股股东人数 | 120 | | 2、出席会议的股东所持有的表决权数量 | 32,862,618 | | 普通股股东所持有表决权数量 | 32,862,618 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 7.9662 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比 ...

北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 源: - YUAN LAW OFFICES 为出具本法律意见书,本所指派律师现场见证了本次股东大会,查阅了公司 提供的与本次股东大会有关的文件和资料,并进行了必要的审查和验证。在前述 审查和验证的过程中,本所律师得到公司的如下承诺和保证:就本所认为出具本 法律意见书所必需审查的事项而言,公司已经提供了全部相关的原始书面材料、 副本材料或口头证言,该等资料均属真实、准确、完整及有效,有关复印件与原 件一致、副本与正本一致。 在本法律意见书中,本所律师仅对本次股东大会的召集、召开程序、出席会 议人员资格、召集人资格、会议表决程序、表决结果等所涉及的有关法律问题发 表意见,不对本次股东大会审议的议案内容以及该等议案所表述的事实或数据的 真实性及准确性发表意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具目以前已经 发生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚 ...

Core Viewpoint - The company BGI Genomics has launched the T1+ desktop sequencer, which is capable of producing Tb-level data within 24 hours, marking a significant advancement in genome sequencing technology [1] Group 1: Product Launch - BGI Genomics officially released the T1+ desktop sequencer at the AGBT conference on February 24 [1] - The T1+ can complete PE150 sequencing tasks in 24 hours and SE50 sequencing in a maximum of 7 hours [1] - It is the world's first desktop sequencer that can output Tb-level data within 24 hours [1]

证券代码：688114 证券简称：华大智造 公告编号：2025-010 深圳华大智造科技股份有限公司 关于注销部分募集资金现金管理专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金现金管理情况 二、募集资金现金管理专用结算账户的注销情况 截至本公告披露日，公司在珠海华润银行股份有限公司深圳福田支行（银行 账号：222256121282600001）购买的理财产品均已全部到期赎回，且不再使用该 账户。根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 及公司《募集资金管理制度》的相关规定，公司已于近日办理完毕该账户的注销 手续。 特此公告。 深圳华大智造科技股份有限公司 深圳华大智造科技股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开第二届董事会第五次会议、第二届监事会第五次会议，审议通过了《关于 使用部分暂时闲置自有资金及募集资金进行现金管理的议案》，同意公司在确保 不影响公司募 ...